Mar 9, 2012 by Brian Orelli, PhDApproval Likely, but Details Still ImportantDetails will determine the sales potential of Gilead's quad HIV drug.
Mar 8, 2012 by Brian Orelli, PhDGunning for Best-in-Class StatusJ&J tries to take out Provenge; Dendreon offers a hug.
Mar 7, 2012 by Brian Orelli, PhDApproval, Baby!Discovery Labs' respiratory distress syndrome treatment Surfaxin is finally approved.
Mar 6, 2012 by Brian Orelli, PhDThe 2 Lines That Cost Investors MillionsOncothyreon's interim look fails to impress.
Mar 5, 2012 by Brian Orelli, PhDApproved Drug + Approved Drug = Rejection?Merck just can't seem to get its Zetia-Lipitor combination approved.
Mar 2, 2012 by Brian Orelli, PhDThis Drugmaker Is Covering All Its BillsDon't laugh, that's an important first step.
Feb 29, 2012 by Brian Orelli, PhDPharmas Turn a Healthy Profit by Treating Rare DiseasesExamining orphan drugs on Rare Disease Day.
Feb 29, 2012 by Brian Orelli, PhDThose Europeans Will Approve (Almost) AnythingToo bad most of the money to be made is stateside.
Feb 29, 2012 by Brian Orelli, PhDThis Government Agency Can Make Drugmakers BillionsAnd it ain't the FDA.
Feb 28, 2012 by Brian Orelli, PhDThis Biotech Is Up 14%, and It's Just Getting StartedIt's all relative in biotech phase 1 data.
Feb 28, 2012 by Brian Orelli, PhDSlow and Steady Has Investors FleeingBenlysta sales fail to impress.
Feb 28, 2012 by Brian Orelli, PhDCan J&J's New Leader Turn Things Around?So long and thanks for all the recalls, Bill Weldon.
Feb 27, 2012 by Brian Orelli, PhDDrama? Of Course. It's Dendreon.Pre-announcing sales didn't kill the drama.
Feb 24, 2012 by Brian Orelli, PhDBiotech Investors, Take Note: Margin of Victory MattersChelsea Therapeutics gets a lukewarm win.
Feb 23, 2012 by Brian Orelli, PhDThe Death of a Dividend Aristocrat?After spinning off its drug division, Abbott won't keep its dividend the same.
Feb 23, 2012 by Brian Orelli, PhDYeah, I'd Call That a Confident RecommendationVIVUS' Qnexa snags a 20-2 thumbs-up for approval.
